Alteogen Biologics Secures Product Approval for Eylea Biosimilar in Saudi Arabia
Approval Led by MENA Partner SPIMACO
Accelerating Entry into 15 Middle Eastern and North African Countries
Alteogen Biologics has secured a foothold for entry into the Middle East and North Africa (MENA) market by obtaining product approval for its Eylea biosimilar, 'ALT-L9,' in Saudi Arabia.
On the 19th, Alteogen Biologics, a subsidiary of Alteogen, announced that its MENA region partner, SPIMACO, has received product approval for ALT-L9 from the Saudi Food and Drug Authority (SFDA).
SPIMACO is a leading pharmaceutical company in Saudi Arabia and serves as the partner responsible for the production, marketing, distribution, and commercialization of ALT-L9 in 16 MENA countries. This approval marks an example of Alteogen Biologics obtaining overseas product registration through a global partnership.
The Saudi SFDA is one of the major regulatory agencies in the Middle East, and many MENA countries refer to SFDA approval results during their own regulatory review processes. Accordingly, the company expects that this approval will expedite the registration processes in key MENA countries, including the United Arab Emirates (UAE). Currently, regulatory review is underway in the UAE.
ALT-L9 is a biosimilar of Eylea, a vascular endothelial growth factor (VEGF) inhibitor used to treat retinal diseases such as macular degeneration. Alteogen Biologics has demonstrated equivalence to the original drug through global Phase 3 clinical trials and has received product approval from both the European Medicines Agency (EMA) and the Ministry of Food and Drug Safety (MFDS) in Korea.
The MENA region, with a population exceeding 500 million, is considered a growth market with high demand for retinal disease treatments, such as diabetic retinopathy and macular edema.
Heejung Ji, CEO of Alteogen Biologics, stated, "SFDA approval in Saudi Arabia is a significant milestone for expanding into the Middle East and North Africa market," adding, "Based on this approval, we will expedite the regulatory process in key countries, including the UAE, and continue to drive the global expansion of ALT-L9."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
In 2024, SPIMACO signed an exclusive agreement with Alteogen Biologics for the rights to ALT-L9 in 16 MENA countries. SPIMACO is working to obtain regulatory approval and commercialize ALT-L9, leveraging its local manufacturing capabilities and regional network.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.